<DOC>
	<DOCNO>NCT00987675</DOCNO>
	<brief_summary>RATIONALE : High-intensity focus ultrasound ablation use high-energy sound wave kill tumor cell . PURPOSE : This phase II trial study side effect high-intensity focus ultrasound ablation see well work treat patient progressive prostate cancer .</brief_summary>
	<brief_title>High-Intensity Focused Ultrasound Ablation Treating Patients With Progressive Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate side effect patient-reported quality life outcome index ( large ) lesion treatment high-intensity focus ultrasound ablation patient progressive ≤ T3b , N0 , M0 prostate cancer . Secondary - To determine success treatment demonstrate absence cancer treat ablated area 6 month post-treatment transrectal ultrasound biopsy . - To evaluate prostate-specific antigen ( PSA ) kinetics index lesion ablation treatment patient . - To evaluate proportion patient , undergo index lesion control treatment , require androgen blockade 12-month follow-up . OUTLINE : Patients undergo transrectal high-intensity focus ultrasound ablation ( HIFU ) index lesion identifiable secondary lesion . Patients evaluate 6 month may repeat HIFU treatment . Patients undergo MRI ultrasound baseline periodically thereafter , blood sample collect periodically PSA , renal function , full blood count , testosterone level . Patients also complete questionnaire ( IPSS , IPSS-QOL , ICS , FACT-P , IIEF-5 ) baseline ; 6 week ; 3 , 6 , 9 12 month . After completion study treatment , patient follow 2 6 week 3 , 6 , 9 , 12 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm prostate cancer transrectal ultrasound transperineal template prostate biopsy meet follow criterion : Stage ≤ T3b , N0 , M0 disease Gleason score ≤ 8 Serum PSA ≤ 20 ng/mL No metastatic disease nodal spread stag CT MRI Negative bone scan within past 6 month Index lesion secondary lesion volume ≥ 0.5 cc MRI Secondary lesion include treatment provide ≥ 1 neurovascular bundle 4050 % prostatic tissue preserve PATIENT CHARACTERISTICS : Able tolerate transrectal ultrasound Able undergo major surgery assess consultant anesthesiologist Able undergo MRI scanning ( i.e. , severe claustrophobia , permanent cardiac pacemaker , metallic implant ) No urethral stricture presence metal implant stent urethra No prostatic calcification cyst ( transrectal ultrasound ) would interfere effective delivery HIFU therapy No allergy latex PRIOR CONCURRENT THERAPY : No prior radiotherapy No prior treatment follow : Transurethral resection prostate equivalent procedure within past 2 year Highintensity focus ultrasound ablation ( HIFU ) Cryosurgery Thermal microwave therapy prostate No prior significant rectal surgery prevents insertion transrectal HIFU probe More 12 month since prior androgen suppression hormone treatment prostate cancer</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
</DOC>